Abstract:Abstract Background Propofol is used to induce sadation or general anesthesia for procedures. Adjuvants, such as remifentanil characterized by a rapid onset of analgesia and a very short duration of action, which was proved to be an effective opioid receptor agonist considering its effective inhibition of autonomic nervous reflex during endoscopy. Meanwhile, it brings respiratory depression and hypoxia in particular, but there is few reports to explore the optimal dose of remifentanil during gastroscopy so far. So we design this randomized controlled trial (RCT) to identify an optimal remifentanil dosage in patients receiving gastroscopy. Methods A total of 200 patients were recruited and randomly assigned to receive one of four doses of remifentanil: 0 (control group), 1.25μg/ml (PR1 group), 2.5μg/ml (PR2 group), 5μg/ml (PR3 group) combined with propofol anesthesia. The primary outcome is the incidence of hypoxia. The secondary outcomes are the dosage of propofol, patients’ awakening time, and perioperative adverse reactions such as hypotension, hypertension, bradycardia, tachycardia, body movements, nausea and vomiting. Results The onset time of PR2 (19 ± 2 s) and PR3(18 ± 4 s) group were shorter than control group (21 ± 3 s). Awaking time in PR2 (1.6 ± 0.4 min) and PR3 (1.7 ± 0.6 min) groups were significantly less than control group (4.1± 1.1min). The dose of propofol in PR2(90 ± 11 mg) and PR3(87±12 mg) groups were also significantly less than control group( 180 ± 20 mg)。The incidence of hypoxia and increase the flow of oxygen and jaw lift in PR2 group were significantly decreased from 38% to 14% and 32% to 10% compared with the control group, respectively (p<0.01).While the incidence of hypoxia in PR3 group was increased to 46%, higher than other groups (p<0.01). Total number of Sedation-related adverse events in PR2 was significantly decreased from 32% to 8% (p=0.03). Conclusions Both 2.5μg/ml (PR2) and 5μg/ml (PR3) remifentanil combined with propofol used in gastroscopy can reduce the onset time、awaking time and the amount of propofol. But the incidence of hypoxia and total number of sedation-related adverse events in PR2 group were significantly decreased compared with other groups. In our study, 2.5μg/ml remifentanil combined with propofol in gastroscopy is an optimal remifentanil dosage. Trial registration: ClinicalTrials.gov, ChiCTR2000029216.

Deep sedation using propofol target-controlled infusion for gastrointestinal endoscopic procedures: a retrospective cohort study

Sedation and Safety of Propofol for Therapeutic Endoscopic Retrograde Cholangiopancreatography.

Effects of intravenous lidocaine on hypoxemia induced by propofol-based sedation for gastrointestinal endoscopy procedures: study protocol for a prospective, randomized, controlled trial

Safety and Risk Factors of Propofol for Conscious Sedation During in Gastrocopy

High-flow Nasal Cannula Oxygen Therapy and Hypoxia During Gastroscopy with Propofol Sedation: a Randomized Multicenter Clinical Trial.

A comparison between target-controlled and manually controlled propofol infusions in patients undergoing routine surgical procedures.

Sedative effects of propofol and risk factors for excessive sedation in the endoscopic treatment of biliary and pancreatic diseases

Optimizing sedation in gastroscopy: a study on the etomidate/propofol mixture ratio

The effectiveness of esketamine and propofol versus dezocine and propofol sedation during gastroscopy: A randomized controlled study

Etomidate Versus Propofol for Monitored Anesthesia Care During Endoscopic Retrograde Cholangiopancreatography: A Prospective Randomized Controlled Trial

Moderate and deep nurse-administered propofol sedation is safe

Sedation with a 1:1 mixture of etomidate and propofol for gastroscopy in hypertensive elderly patients

Capnographic Monitoring Reduces Hypoxia Incidence in Older Patients Undergoing Gastrointestinal Endoscopy under Propofol Sedation: Study Protocol for a Multicenter Randomized Controlled Trial

Impact of intravenous and topical lidocaine on clinical outcomes in patients receiving propofol for gastrointestinal endoscopic procedures: a meta-analysis of randomised controlled trials

Comparison of 95% Effective Dose of Remimazolam Besylate and Propofol for Gastroscopy Sedation on Older Patients: A Single‐centre Randomized Controlled Trial

Effect Assessment of Single Propofol Sedation in Procedures of Painless Gastrointestinal Endoscopy

Target-Controlled Infusion of Propofol in Training Anesthesiology Residents in Colonoscopy Sedation: A Prospective Randomized Crossover Trial

Propofol-alone sedative efficacy in observational biliopancreatic endoscopic ultrasound

Efficacy and Safety of Propofol combined with different doses of Remifentanil for gastroscopy: A-randomized controlled trial

Efficacy and safety of intravenous lidocaine in propofol-based sedation for ERCP procedures: a prospective, randomized, double-blinded, controlled trial

Associated sedation of propofol and midazolam in small dosage and gastroscopy